Comorbidities, age and period of diagnosis influence treatment and outcomes in early breast cancer. Issue 9 (27th December 2018)

• Record Type: Journal Article
• Authors: Minicozzi, Pamela; Van Eycken, Liesbet; Molinie, Florence; Innos, Kaire; Guevara, Marcela; Marcos‐Gragera, Rafael; Castro, Clara; Rapiti, Elisabetta; Katalinic, Alexander; Torrella, Ana; Žagar, Tina; Bielska‐Lasota, Magdalena; Giorgi Rossi, Paolo; Larrañaga, Nerea; Bastos, Joana; Sánchez, Maria José; Sant, Milena
• Is Part Of: International journal of cancer. Volume 144:Issue 9(2019)
• Page Start: 2118
• Page End: 2127
• Publication Date: 2018-12-27
• Subjects: early breast cancer -- comorbidities -- standard treatment -- outcomes -- population study; Cancer -- Periodicals; Cancer -- Prevention -- Periodicals; 616.994
• DOI: 10.1002/ijc.31974
• Languages: English
• ISSNs: 0020-7136

Abstract

Abstract : Survival for breast cancer (BC) is lower in eastern than northern/central Europe, and in older than younger women. We analysed how comorbidities at diagnosis affected whether selected standard treatments (STs) were given, across Europe and over time, also assessing consequences for survival/relapse. We analysed 7581 stage I/IIA cases diagnosed in 9 European countries in 2009–2013, and 4 STs: surgery; breast‐conserving surgery plus radiotherapy (BCS + RT); reconstruction after mastectomy; and prompt treatment (≤6 weeks after diagnosis). Covariate‐adjusted models estimated odds of receiving STs and risks of death/relapse, according to comorbidities. Pearson's R assessed correlations between odds and risks. The z ‐test assessed the significance of time‐trends. Most women received surgery: 72% BCS; 24% mastectomy. Mastectomied patients were older with more comorbidities than BCS patients ( p < 0.001). Women given breast reconstruction (25% of mastectomies) were younger with fewer comorbidities than those without reconstruction ( p < 0.001). Women treated promptly (45%) were younger than those treated later ( p = 0.001), and more often without comorbidities ( p < 0.001). Receiving surgery/BCS + RT correlated strongly ( R = −0.9), but prompt treatment weakly ( R = −0.01/−0.02), with reduced death/relapse risks. The proportion receiving BCS + RT increased significantly ( p < 0.001) with time in most countries. This appears to be the first analysis of the influence of comorbidities on receiving STs, and of consequences for outcomes. Increase in BCS + RT with time is encouraging. Although women without comorbidities usually received STs, elderly patients often received non‐standard less prompt treatments, irrespective of comorbidities, with increased risk of mortality/relapse. All women, particularly the elderly, should receive ST wherever possible to maximise the benefits of modern evidence‐based treatments. What's new?: This is the first Europe‐wide study (37 cancer registries, 9 countries) analysing the effect of comorbidities on whether women with early breast cancer (diagnosed 2009–13) receive standard treatments. Women with no comorbidities usually received standard treatments, but elderly women often received less prompt and non‐standard treatments, irrespective of comorbidities, with increased probability of relapse and mortality. All women, particularly the elderly, should receive standard treatments wherever possible to maximize the benefits of modern evidence‐based approaches.